Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Pulsoni

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|September 18, 2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphomaStefano Luminari, Maria Goldaniga, Marina Cesaretti, et al.
Cancers|July 2, 2021
High Basal Maximal Standardized Uptake Value (SUV<sub>max</sub>) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term RelapseGiovanni Manfredi Assanto, Giulia Ciotti, Mattia Brescini, et al.
Leukemia & Lymphoma|October 29, 2009
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphomaElena Cavalieri, Angela Matturro, Giorgia Annechini, et al.
European Journal of Haematology|December 21, 2025
Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective AnalysisDeborah Kasmi, Maria Laura Bisegna, Ida Carmosino, et al.
Cancer Medicine|March 19, 2016
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 yearsBeatrice Casadei, Cinzia Pellegrini, Alessandro Pulsoni, et al.
Hematological Oncology|December 15, 2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective studyGiovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, et al.
British Journal of Haematology|May 1, 2021
The current role of interferon in hairy cell leukaemia: clinical and molecular aspectsGiovanni M Assanto, Costantino Riemma, Francesco Malaspina, et al.
BMC Infectious Diseases|September 20, 2014
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virusRoberto Bruni, Cinzia Marcantonio, Alessandro Pulsoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life ExperienceMarina Moretti, Anna Marina Liberati, Luigi Rigacci, et al.
Chemotherapy|December 22, 2022
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic TransplantFulvia Fanelli, Stefan Hohaus, Maria Cantonetti, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|September 18, 2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphomaStefano Luminari, Maria Goldaniga, Marina Cesaretti, et al.
Cancers|July 2, 2021
High Basal Maximal Standardized Uptake Value (SUV<sub>max</sub>) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term RelapseGiovanni Manfredi Assanto, Giulia Ciotti, Mattia Brescini, et al.
Leukemia & Lymphoma|October 29, 2009
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphomaElena Cavalieri, Angela Matturro, Giorgia Annechini, et al.
European Journal of Haematology|December 21, 2025
Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective AnalysisDeborah Kasmi, Maria Laura Bisegna, Ida Carmosino, et al.
Cancer Medicine|March 19, 2016
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 yearsBeatrice Casadei, Cinzia Pellegrini, Alessandro Pulsoni, et al.
Hematological Oncology|December 15, 2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective studyGiovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, et al.
British Journal of Haematology|May 1, 2021
The current role of interferon in hairy cell leukaemia: clinical and molecular aspectsGiovanni M Assanto, Costantino Riemma, Francesco Malaspina, et al.
BMC Infectious Diseases|September 20, 2014
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virusRoberto Bruni, Cinzia Marcantonio, Alessandro Pulsoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 25, 2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life ExperienceMarina Moretti, Anna Marina Liberati, Luigi Rigacci, et al.
Chemotherapy|December 22, 2022
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic TransplantFulvia Fanelli, Stefan Hohaus, Maria Cantonetti, et al.
Pageof 11